500 River Ridge Drive
Norwood, MA 02062
United States
617 963 0100
https://www.corbuspharma.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 19
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Yuval Cohen Ph.D. | CEO & Director | 907,78k | N/D | 1975 |
Mr. Sean F. Moran CPA, M.B.A. | Chief Financial Officer | 609,28k | N/D | 1958 |
Ms. Lindsey Smith | Head of Corporate Communications & Patient Advocacy | N/D | N/D | N/D |
Ms. Christina Bertsch | Head of Human Resources | N/D | N/D | N/D |
Dr. Dominic Smethurst M.A., M.D. | Chief Medical Officer | N/D | N/D | 1975 |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
L'ISS Governance QualityScore di Corbus Pharmaceuticals Holdings, Inc. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 4; diritti degli azionisti: 4; retribuzione: 9.